Gastroenterological safety of IL-17 inhibitors: a systematic literature review.
Fiche publication
Date publication
juillet 2021
Journal
Expert opinion on drug safety
Auteurs
Membres identifiés du Cancéropôle Est :
Pr GILLET Pierre, Pr JOUZEAU Jean-Yves, Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Caron B, Jouzeau JY, Miossec P, Petitpain N, Gillet P, Netter P, Peyrin-Biroulet L
Lien Pubmed
Résumé
Interleukin 17 is a proinflammatory cytokine considered to play a significant role in the immunopathogenesis of many chronic immune-mediated disorders. Interleukin 17 inhibitors provide an excellent treatment option for patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. However, Interleukin 17 inhibitors have been suspected of worsening or triggering new-onset inflammatory bowel disease.
Mots clés
Crohn’s disease, IL-17 inhibitor, brodalumab, ixekizumab, safety, secukinumab, ulcerative colitis
Référence
Expert Opin Drug Saf. 2021 Jul 26;: